finance
Biotalys Reports 2025 Financial Results with €8.0 Million Cash Runway and Strategic Refocus
Biotalys announced its consolidated financial results for 2025 on April 29, 2026, showing year-end cash and cash equivalents of €8.0 million, sufficient until the end of May 2026. The company detailed regulatory approvals for its biofungicide EVOCA and progress on pipeline programs amid a strategic refocus to streamline operations. Management hosted a conference call to discuss the updates.
agfundernews.comAudio version
Tap play to generate a narrated version.
Ghent, Belgium (Substrate) -- Biotalys announced consolidated financial results for 2025 on April 29, 2026, prepared in accordance with IFRS as adopted by the European Union. The annual report, including the full financial report for 2025, is published on the company's website. 0 million, providing a financial runway until the end of May 2026.
The company is negotiating with investors regarding financing options as of April 29, 2026. Biotalys announced its intention to proceed with a strategic refocus in early February 2026, which the board confirmed on April 29, 2026. As part of this, Biotalys is proceeding with a streamlined operational model and has suspended its early-stage activities to reduce operating expenses while safeguarding the long-term value of its technology platform.
Biotalys will prioritize the development and regulatory advancement of its lead biofungicide assets and focus commercial preparation efforts on markets with the highest near-term potential. The strategic refocus aims to result in a significant reduction of cash burn until the end of 2028.
Management hosted a conference call and live webcast at 15:00 CEST, 14:00 GMT, or 09:00 AM ET on April 29, 2026, to discuss the results and outlook.
EPA for its first candidate biofungicide EVOCA, announced in December 2025. EVOCA controls the fungal diseases Botrytis (grey mold) and powdery mildew for fruit and vegetable growers. The Dutch regulator provided a positive recommendation for EVOCA in 2025, with the Dutch Board for the Authorisation of Plant Protection Products (CTGB) recommending approval of its active ingredient throughout the European Union.
The Dutch Institute for Health and Environment (RIVM) confirmed no critical areas of concern for EVOCA and proposed its low-risk classification in 2025. U.S.
